[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505023":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":57,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Region Västerbotten","OTHER_GOV",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Cervix cancer",null,"Newly diagnosed cervix cancer.",[13],"Diagnostic Test: FDG-PET\u002FCT and FDG-PET\u002FMRI",{"label":15,"type":10,"description":16,"interventionNames":17},"Endometrial cancer","Newly diagnosed endometrial cancer.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Ovarian cancer","Strong suspicion of newly diagnosed epithelial ovarian cancer; histopathological confirmation required within 6 months after inclusion.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","FDG-PET\u002FCT and FDG-PET\u002FMRI","Intravenous injection of FDG 3 MBq\u002Fkg. Intravenous injection of Dotarem 279.3 mg\u002Fml, 0.2 ml\u002Fkg.",[9,15,19],[29],{"name":30,"affiliation":31,"role":32},"Sara Strandberg, MD, PhD","Department of Radiation Sciences, Umea University\u002FRadiology, Umea University Hospital","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Erika Figaro","CONTACT","+46907850499","erika.figaro@regionvasterbotten.se",{"name":30,"role":36,"phone":40,"phoneExt":10,"email":41},"+46907850000","sara.strandberg@umu.se",[43],{"facility":44,"status":45,"city":46,"state":10,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Centre for Gynecology and Obstetrics, Umea University Hospital","RECRUITING","Umeå","Sweden","SE",{"type":50,"coordinates":51},"Point",[52,53],20.25972,63.82842,{"lat":53,"lon":52},[56],{"name":35,"role":36,"phone":10,"phoneExt":10,"email":10},{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[60],{"name":61,"class":62},"Umeå University","OTHER","100505023","prognostic-and-diagnostic-added-value-of-medical-imaging-in-gynecological-cancer-prodigyn-100505023",false,"NCT05855941","Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)","Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer (PRODIGYN)","PRODIGYN","Inclusion Criteria:\n\n* Previously untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer.\n* Known clinical FIGO stage.\n* \\>18 years old.\n* No other known current or previous malignancy within the last 10 years.\n\nExclusion Criteria:\n\n* Imaging findings suggestive of other primary malignancy.\n* Previously included suspected epithelial ovarian cancer, later confirmed to be other diagnosis than epithelial ovarian cancer or \"cancer abdominis\".\n* MRI incompatible devices or patient unable to undergo MRI.","FEMALE","18 Years",{"count":74,"type":75},120,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are:\n\n* Does advanced medical imaging predict survival?\n* Can advanced medical imaging improve radiotherapy target planning?\n* Are advanced medical imaging results associated with risk markers found in tumor tissue?\n\nParticipants will\n\n* Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months.\n* Be subject to clinical follow-up for five years.",[79,80,81],"Cervix Cancer","Endometrial Cancer","Epithelial Ovarian Cancer",[83,84,79,80,81],"Positron Emission Tomography-Computed Tomography","Magnetic Resonance Imaging","2024-12-10",{"date":87,"type":88},"2024-12-16","ACTUAL",{"date":90,"type":88},"2023-05-23",{"date":92,"type":75},"2032-05",{"name":5,"class":6},1]